Guardian Pharmacy Services (NYSE:GRDN) Announces Earnings Results, Misses Expectations By $0.05 EPS

Guardian Pharmacy Services (NYSE:GRDN) announced its earnings results on Monday. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.05), Zacks reports. Guardian Pharmacy Services had a negative return on equity of 52.41% and a negative net margin of 6.90%. Guardian Pharmacy Services updated its FY 2025 guidance to EPS.

Guardian Pharmacy Services Stock Up 3.3%

NYSE:GRDN traded up $0.96 during trading hours on Monday, reaching $29.76. The company had a trading volume of 504,629 shares, compared to its average volume of 213,949. Guardian Pharmacy Services has a twelve month low of $17.78 and a twelve month high of $30.39. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -19.58 and a beta of 0.96. The business’s 50-day simple moving average is $26.76 and its two-hundred day simple moving average is $23.88.

Institutional Trading of Guardian Pharmacy Services

Several large investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new stake in Guardian Pharmacy Services in the 1st quarter valued at about $233,000. JPMorgan Chase & Co. grew its stake in Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company’s stock valued at $128,000 after acquiring an additional 1,956 shares during the period. Legal & General Group Plc increased its holdings in shares of Guardian Pharmacy Services by 1,783.1% during the second quarter. Legal & General Group Plc now owns 14,895 shares of the company’s stock valued at $317,000 after acquiring an additional 14,104 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Guardian Pharmacy Services by 121.1% in the 2nd quarter. Rhumbline Advisers now owns 16,174 shares of the company’s stock worth $345,000 after purchasing an additional 8,860 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Guardian Pharmacy Services in the 2nd quarter valued at $214,000.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Oppenheimer assumed coverage on Guardian Pharmacy Services in a research note on Friday, October 10th. They issued an “outperform” rating and a $30.00 price target for the company. Wall Street Zen cut Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a report on Sunday. Truist Financial increased their target price on shares of Guardian Pharmacy Services from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Guardian Pharmacy Services in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.